Vertex, Concert Strike Deal on Investigational Therapy VX-561

Vertex, Concert Strike Deal on Investigational Therapy VX-561

294643

Vertex, Concert Strike Deal on Investigational Therapy VX-561

Vertex Pharmaceuticals has made a $32 million purchase from Concert Pharmaceuticals related to future milestones from the 2017 agreement when Vertex purchased Concert’s investigational treatment for cystic fibrosis (CF), VX-561. According to Roger Tung, PhD, Concert’s president and CEO, the purchase will help Concert as it continues clinical development of an experimental treatment for alopecia areata, which is a type of sudden hair loss caused by the immune system attacking hair follicles. “This transaction provided an…

You must be logged in to read/download the full post.